Search results
Flu Breakthrough: Vanderbilt Scientists Discover Powerful New Weapon
SciTechDaily· 1 day agoVanderbilt University researchers have identified potent monoclonal antibodies against influenza B, showcasing a promising avenue for treatment and preventative strategies ...
House Republicans’ Attempts to Attack Fauci Go Wildly Off Rails
The New Republic via Yahoo News· 4 days ago“No—I’m on the record, and I want to make sure that this is clear: that I developed a monoclonal ...
Fauci Testimony Turns Chaotic: 'Most Insane Hearing I've Attended'
Rolling Stone· 4 days agoAnthony Fauci over his involvement in the response to the Covid-19 pandemic. Fauci was summoned...
A Guide to Managing Covid This Summer
New York Times· 4 days agoKP.2, one of these variants, now accounts for 28.5 percent of cases, and data from the Centers for Disease Control and Prevention shows a small increase...
Invivyd aligns with FDA on rapid mAb trial pathway By Investing.com
Investing.com· 7 days agoFood and Drug Administration (FDA) on a new clinical trial pathway for the expedited development of ...
mRESVIA’s FDA approval paves the way for mRNA vaccines across multiple indications
Clinical Trials Arena via Yahoo Finance· 1 day agoThe RSV market has altered substantially in recent years owing to the emergence of novel vaccines...
The Push to Get More People Into Long COVID Studies
Medscape· 3 days agoWhen Ezra Spier was diagnosed with long COVID in late 2022, his main symptom, postexertional malaise, caused fatigue so severe that it forced him to quit...
After key rare disease win, Annexon eyes $144 million raise - San Francisco Business Times
The Business Journals· 2 days agoAnnexon Inc. hopes to sell $125 million of stock following a late-stage clinical trial of a drug...
High Confidence AD Drug Donanemab Will Get FDA Panel Nod
Medscape· 3 days agoThe Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug...
Anti-CD20 HGG Linked to Serious Infection Risk in MS
Medscape· 10 hours agoHypogammaglobulinemia is a known risk linked to B-cell–depleting therapies, but a real-world study has specified the risk and risk factors in multiple...